FUSN logo

Fusion Pharmaceuticals Inc. Common Shares


FUSN: Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.


Show FUSN Financials

Consumer Interest
SEC Filings

Recent trades of FUSN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by FUSN's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Actinium-225 and checkpoint inhibitor combination therapy Sep. 20, 2022
  • Patent Title: Endosialin-binding antibody May. 03, 2022
  • Patent Title: Igf-1r monoclonal antibodies and uses thereof Oct. 09, 2018
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of FUSN in WallStreetBets Daily Discussion


Recent insights relating to FUSN

CNBC Recommendations

Recent picks made for FUSN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FUSN

Corporate Flights

Flights by private jets registered to FUSN